ArticleBMC gastroenterology2025
A Multi-marker model based on serum IL-10 predicts response to conversion immunochemotherapy in gastric cancer patients: a retrospective cohort study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of plasma lipidomic biomarkers for prognostic stratification in advanced gastric cancer treated with PD-1 inhibitor plus chemotherapy.Frontiers in immunology · 2026Article
- Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundConversion immunochemotherapy may enable curative surgery in patients with initially unresectable locally advanced gastric cancer, but its response rate remains low. Little evidence has shown how to easily predict therapeutic efficacy from hematological biomarkers, apart from tissue biomarkers. This study aimed to identify predictive factors for treatment response from hematological biomarkers and propose strategies for non-responsive patients.
methodsClinical and laboratory data from 153 PD-L1 negative and microsatellite stable advanced gastric cancer patients treated with conversion immunochemotherapy followed by radical gastrectomy were retrospectively analyzed. Correlations between key indicators and treatment outcomes were assessed, and a nomogram was developed to predict tumor regression grade (TRG).
resultsTRG was strongly associated with the prognosis of advanced gastric cancer treated with conversion immunochemotherapy. Factors significantly related to TRG included hypertension, pre-treatment serum albumin levels, tumor size, post-treatment serum IL-10, IFN-γ, TNF-α, and changes in tumor-associated carbohydrate antigens before and after treatment. Hypertension, pre-treatment serum albumin levels, post-treatment IL-10 levels, and restoration in tumor-associated carbohydrate antigens were identified as independent predictors of TRG.
conclusionDynamic monitoring of serum albumin, IL-10, and tumor-associated carbohydrate antigens can help assess treatment response and identify patients sensitive to conversion immunochemotherapy. For non-responsive patients, strategies such as the associations observed require validation in prospective interventional trials before specific interventions can be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.